Can Fite Biofarma (Can Fite Biofarma) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Can Fite Biofarma's Free Cash Flow for the three months ended in Dec. 2023 was $0.00 Mil. Can Fite Biofarma's Revenue for the three months ended in Dec. 2023 was $0.16 Mil. Therefore, Can Fite Biofarma's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Can Fite Biofarma's current FCF Yield % is -79.50%.

The historical rank and industry rank for Can Fite Biofarma's FCF Margin % or its related term are showing as below:

CANF' s FCF Margin % Range Over the Past 10 Years
Min: -5283.47 Med: -1157.13 Max: -109.63
Current: -1136.2

During the past 13 years, the highest FCF Margin % of Can Fite Biofarma was -109.63%. The lowest was -5283.47%. And the median was -1157.13%.

CANF's FCF Margin % is ranked worse than
77.33% of 1032 companies
in the Biotechnology industry
Industry Median: -148.935 vs CANF: -1136.20

Can Fite Biofarma FCF Margin % Historical Data

The historical data trend for Can Fite Biofarma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma FCF Margin % Chart

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-545.62

-1,584.40

-1,156.98

-1,334.57

-1,136.20

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Can Fite Biofarma's FCF Margin %

For the Biotechnology subindustry, Can Fite Biofarma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's FCF Margin % falls into.

Can Fite Biofarma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Can Fite Biofarma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-8.442	/	0.743
	=	-1,136.20 %

Can Fite Biofarma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	0.155
	=	0.00 %

Can Fite Biofarma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).